Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial

NCT04332822 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT04332822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04332822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial
Lead sponsor
Nordic Lymphoma Group
Phase
Phase 3
Overall status
Recruiting
Start date
August 19, 2020
Completion date
December 28, 2028
Enrollment
300 (estimated)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, dlbcl